Welcome to our dedicated page for Hutchmed (China) SEC filings (Ticker: HCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HUTCHMED (China) Limited filings document a foreign private issuer with American depositary shares linked to its ordinary-share capital. Form 6-K submissions furnish press releases, annual report materials, shareholder-meeting documents, total voting-rights notices, and governance disclosures for the company’s Nasdaq, AIM and HKEX-listed securities.
The filing record covers HUTCHMED’s targeted therapy and immunotherapy business, China regulatory updates, oncology and immunology pipeline disclosures, licensed product matters, and annual reporting. Other recurring filing subjects include AGM notices and proxy materials, voting instructions for American depositary share holders, long-term incentive plan award vesting, and capital-structure details for ordinary shares, depositary interests and ADSs.
HUTCHMED (CHINA) LIMITED filed a Form 6-K as a foreign private issuer, indicating that it uses Form 20-F for its annual reports. The filing mainly serves as a cover for two exhibits: an announcement and a press release, each relating to the appointment of an acting chief executive officer. The document is signed on behalf of the company by Chief Financial Officer Johnny Cheng, confirming the company’s authorization of this disclosure.